Search
R-851
go.drugbank.com/drugs/DB05747ExperimentalR-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells.
Egg phospholipids
go.drugbank.com/drugs/DB14233ApprovedWithdrawnEgg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.
Mixtures: LIPOFUNDIN N EMULSION FOR INFUSION 20 %Gluconolactone
go.drugbank.com/drugs/DB04564ApprovedGluconolactone is a naturally-occurring food additive used as a sequestrant, an acidifier, or a curing, pickling, or leavening agent. It is a cyclic ester of D-gluconic acid.
Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase
go.drugbank.com/drugs/DB18681ExperimentalIt comprises autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that had been genetically modified ex vivo with EFS-ADA LV. … Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy.
Sulfaisodimidine
go.drugbank.com/drugs/DB13283ExperimentalSulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been
Iron isomaltoside 1000
go.drugbank.com/drugs/DB12208ApprovedInvestigationalWithdrawnIron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia.
Benoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.
Medetomidine
go.drugbank.com/drugs/DB11428ExperimentalVet approvedIn the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. … Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma.
Distigmine
go.drugbank.com/drugs/DB13694InvestigationalDistigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].
IL15-NK Cell
go.drugbank.com/drugs/DB15725InvestigationalIn particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.